Global Cushing’s Disease Market Insights Forecasts to 2033

• The Global Cushing’s Disease Market Size was Valued at USD 357.12 Billion in 2023
• The Market Size is Growing at a CAGR of 8.24% from 2023 to 2033
• The Worldwide Cushing’s Disease Market Size is Expected to Reach USD 788.23 Billion by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

 

Get more details on this report -

Request Free Sample PDF

 

The Global Cushing’s Disease Market Size is Anticipated to Exceed USD 788.23 Billion by 2033, Growing at a CAGR of 8.24% from 2023 to 2033.

 

Market Overview

Cushing's disease is a rare endocrine disorder caused by excessive cortisol production, typically due to a benign tumor in the pituitary gland, which overstimulates the adrenal glands. This leads to symptoms such as rapid weight gain, particularly in the face and abdomen, muscle weakness, fatigue, high blood pressure, and mood disturbances. The contributing factors for the development of Cushing's disease include prolonged use of corticosteroid medications for conditions like asthma or arthritis, genetic predisposition, and certain tumors in the endocrine system. Increased awareness, advancements in diagnostic imaging, and improved understanding of the role of cortisol regulation have driven more accurate diagnoses. Additionally, rising incidences of obesity and diabetes, which often share overlapping symptoms with Cushing's disease, contribute to greater recognition and investigation of this condition. As per the data provided by the Endocrine Society, Cushing's disease is a rare, annual condition affecting 10-15 people per million, primarily in women aged 20-50.

 

Report Coverage

This research report categorizes the market for the global Cushing’s disease market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global Cushing’s disease market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global Cushing’s disease market.

 

Driving Factors

Cushing's disease is primarily caused by the overproduction of cortisol, often due to benign pituitary tumors. Chronic use of corticosteroid medications, genetic predisposition, and advances in diagnostic technologies have led to more frequent detection. The rising prevalence of obesity, type 2 diabetes, and hypertension has increased screening and awareness. Improved healthcare access and knowledge about the long-term impact of untreated hypercortisolism have also contributed to early diagnosis and intervention. Understanding and managing the underlying causes of Cushing's disease is crucial to providing long-lasting treatment solutions.

 

Restraining Factors

Cushing's disease faces challenges in diagnosis due to its symptoms often overlapping with common conditions, leading to misdiagnosis or delayed detection. The disease's rarity complicates awareness, and treatments like surgery and radiation can be expensive and limited in certain regions. Additionally, the lack of specialized healthcare expertise and advanced diagnostic tools further hinders effective treatment.

 

Market Segmentation

The global Cushing’s disease market share is classified into diagnosis, treatment, and end-user.

• The blood tests segment is expected to hold the largest share of the global Cushing’s disease market during the forecast period.   

Based on the diagnosis, the global Cushing’s disease market is divided into blood tests, salivary cortisol tests, imaging tests, dexamethasone suppression tests, and urinary-free cortisol tests. Among these, the blood tests segment is expected to hold the largest share of the global Cushing’s disease market during the forecast period. Blood tests are the primary diagnostic tool for Cushing's disease due to their simplicity, accessibility, and widespread use in measuring cortisol levels. These tests are often the first line of investigation for suspected cases, and advancements in hormone assay technologies have improved their accuracy. Blood tests remain the cornerstone for early screening and monitoring, driving their dominant share in the diagnosis market.

 

• The medications segment is expected to grow at the fastest CAGR in the global Cushing’s disease market during the forecast period.   

Based on the treatment, the global Cushing’s disease market is divided into medications, surgery, radiation therapy, and adrenalectomy. Among these, the medications segment is expected to grow at the fastest CAGR in the global Cushing’s disease market during the forecast period. Medications are expected to experience significant growth due to the preference for non-invasive therapies, advancements in pharmacological treatments, and new drugs controlling cortisol production. These drugs are used standalone or in combination, especially for patients not ideal for surgery or those with unresolved conditions. The convenience of medical therapy fuels market expansion.

 

• The specialty clinics segment is expected to grow at the fastest CAGR in the global Cushing’s disease market during the forecast period.   

Based on the end-user, the global Cushing’s disease market is divided into hospitals, specialty clinics, ambulatory surgical centers, and diagnostic centers. Among these, the specialty clinics segment is expected to grow at the fastest CAGR in the global Cushing’s disease market during the forecast period. Specialty clinics are expected to experience significant growth in Cushing's disease treatment segment due to the growing demand for specialized care in managing complex endocrine disorders. These clinics offer targeted expertise, advanced diagnostic tools, and personalized treatment plans, making them preferred for patients seeking focused care. As awareness of Cushing's disease increases, outpatient care for ongoing management is shifting, positioning specialty clinics as key players in the treatment landscape.

 

Regional Segment Analysis of the Global Cushing’s Disease Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the global Cushing’s disease market over the predicted timeframe.

 

Get more details on this report -

Request Free Sample PDF

 

North America is anticipated to hold the largest share of the global Cushing’s disease market over the predicted timeframe. The U.S. is expected to dominate the global Cushing's disease market due to its established healthcare infrastructure, leading pharmaceutical companies, and advanced diagnostic and treatment options. The region's high awareness of rare endocrine disorders, increased healthcare spending, and early adoption of innovative treatments further contribute to its market share. Additionally, favorable reimbursement policies and the rising prevalence of Cushing's disease-related conditions like obesity and diabetes further support its market presence.

 

Asia Pacific is expected to grow at the fastest pace in the global Cushing’s disease market during the forecast period. The region is expected to rapidly grow in the global Cushing's disease market due to rising healthcare infrastructure, increased awareness of rare diseases, and a growing patient population. Government initiatives, advanced diagnostic tools, and a focus on clinical trials and drug development further support market expansion. As awareness and diagnosis improve, Asia-Pacific is poised to become a significant player in the global market.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global Cushing’s disease market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Pfizer Inc. 
• Corcept Therapeutics 
• Novartis AG 
• HRA Pharma 
• Bristol-Myers Squibb Company 
• Strongbridge Biopharma 
• Recordati S.p.A 
• Cyclacel Pharmaceuticals 
• Crinetics Pharmaceuticals 
• Millendo Therapeutics 
• Recorlev 
• Xeris Biopharma Holdings 
• Adrenomed AG 
• Sun Pharmaceutical Industries Ltd. 
• Teva Pharmaceutical Industries Ltd.
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Developments

• In April 2024, Ubie, a global healthcare AI platform, partnered with Cushing's Support and Research Foundation to expedite diagnosis for patients with Cushing's Disease and Cushing's Syndrome.

 

• In March 2020, The U.S. FDA approved Isturisa oral tablets for adults with Cushing's disease who cannot undergo pituitary gland surgery or have undergone surgery but still have the disease.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global Cushing’s disease market based on the below-mentioned segments: 

 

Global Cushing’s Disease Market, By Diagnosis

• Blood Tests
• Salivary Cortisol Tests
• Imaging Tests
• Dexamethasone Suppression Test
• Urinary Free Cortisol Test

 

Global Cushing’s Disease Market, By Treatment

• Medications
• Surgery
• Radiation Therapy
• Adrenalectomy

 

Global Cushing’s Disease Market, By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Diagnostic Centers

 

Global Cushing’s Disease Market, Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa